Behçet's disease: a new target for anti-tumour necrosis factor treatment (Q24675071)

Annals of the Rheumatic Diseases

Europe PubMed Central

title

Behçet's disease: a new target for anti-tumour necrosis factor treatment (English)

0 references

0 references

0 references

P P Sfikakis

1

0 references

language of work or name

English

0 references

publication date

November 2002

0 references

published in

0 references

volume

61 Suppl 2

0 references

issue

Supplement 2

0 references

page(s)

ii51-3

0 references

cites work

A double-blind trial of colchicine in Behçet's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Treatment of Behçet's disease--an update

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

A controlled trial of azathioprine in Behçet's syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Uveitis in Behçet's disease

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Remission of Behçet's syndrome with TNFalpha blocking treatment

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766720

Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab

28 November 2018

1 reference

12 December 2020

Aqueous Humor and Serum Tumor Necrosis Factor-α in Clinical Uveitis

1 reference

12 December 2020

Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease

1 reference

12 December 2020

Effect of infliximab on threatening panuveitis in Behçet's disease

1 reference

12 December 2020

Behçet's disease: an update on the pathogenesis

1 reference

12 December 2020

FK506 treatment of noninfectious uveitis

1 reference

12 December 2020

Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity

1 reference

12 December 2020

Role of gammadelta T lymphocytes in the development of Behçet's disease

1 reference

12 December 2020

Behçet's syndrome: where do we stand?

1 reference

12 December 2020